Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Entrektinibi ainoana aineena lasten etukäteisterapiassa

maanantai 2. marraskuuta 2026 päivittänyt: St. Jude Children's Research Hospital

VAIHE 2 Tutkimus entrektinibistä yksittäisenä aineena lasten etukäteisterapiassa

This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

PRIMARY OBJECTIVE

  • To determine the overall response rate of entrectinib when used as first line therapy in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) (Cohort 1).

SECONDARY OBJECTIVES

  • To estimate the 2-year and 5-year progression free survival (PFS) and overall survival (OS) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused HGG treated with entrectinib as first line therapy (Cohort 1).
  • To estimate the duration of response (DOR) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused HGG treated with entrectinib as first line therapy (Cohort 1).
  • To evaluate the fraction of patients with NTRK1/2/3- or ROS1-fused HGG treated who have second surgeries and a gross-total resection after treatment with entrectinib is achieved, overall and by country and hospital (Cohort 1).
  • To describe the overall response rate of entrectinib when used as first line therapy in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG (Cohort 2).
  • To estimate the 2-year and 5-year PFS and OS in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG treated with entrectinib as first line therapy (Cohort 2).
  • To estimate the duration of response (DOR) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG treated with entrectinib as first line therapy (Cohort 2).
  • To evaluate the fraction of patients with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG who have second surgeries and a gross-total resection after treatment with entrectinib is achieved, overall and by country and hospital (Cohort 2).
  • To describe toxicities experienced by patients younger than 3 years of age treated with entrectinib (Cohort 1 and 2).
  • To evaluate number of patients that are screened for the study and eligible versus enrolled and treated with entrectinib (Cohort 1 and 2).
  • To measure the time intervals (days) from time of initial diagnostic surgery to screening and enrollment in this study (Cohort 1 and 2).

The trial will have 2 cohorts: Cohort 1: patients diagnosed with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) and Cohort 2: patients diagnosed with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG.

Patients receive entrectinib enterally once daily (QD) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients requiring bridging therapy prior to starting entrectinib may receive cyclophosphamide intravenously (IV) over 1 hour on day 1, etoposide IV over 1 hour on day 1 and 2, carboplatin IV over 1 hour on day 2, filgrastim subcutaneously (SC) or IV or pegfilgrastim SC on day 3.

A gross total resection or significant debulking may become possible if a response to entrectinib is seen. If surgical resection is performed and a gross total resection is achieved, 24 cycles of entrectinib will be completed, including those before and after surgery.

After treatment, patients will be followed for 5 years.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

52

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

      • São Paulo, Brasilia, 08270-070
        • Rekrytointi
        • Hospital Santa Marcelina
        • Päätutkija:
          • Sidnei Epelman, MD
        • Ottaa yhteyttä:
      • São Paulo, Brasilia, 04039-001
        • Rekrytointi
        • GRAACC Hospital (Grupo de Apoio ao Adolescente e à Criança com Câncer)
        • Ottaa yhteyttä:
        • Päätutkija:
          • Andrea M. Cappellano, MD
    • São Paulo
      • Barretos, São Paulo, Brasilia, 14784400
        • Rekrytointi
        • Hospital de Câncer de Barretos
        • Ottaa yhteyttä:
        • Päätutkija:
          • Thais J. Vampre, MD
      • Amman, Jordania, 11941
        • Rekrytointi
        • King Hussein Cancer Center
        • Ottaa yhteyttä:
          • Nisreen Amayiri, MD
          • Puhelinnumero: 6376 (962 6) 5300460
          • Sähköposti: namayiri@khcc.jo
        • Päätutkija:
          • Nisreen Amayiri, MD
      • Lima, Peru
        • Rekrytointi
        • Instituto Nacional de Enfermedades Neoplásicas
        • Ottaa yhteyttä:
        • Päätutkija:
          • Rosdali Coronado, MD
    • Tennessee
      • Memphis, Tennessee, Yhdysvallat, 38105
        • Rekrytointi
        • St. Jude Children's Research Hospital
        • Ottaa yhteyttä:
        • Päätutkija:
          • Daniel Moreira, MD, MEd
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

Ei vanhempi kuin 3 vuotta (Lapsi)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria: Screening Phase

  • Age from birth to age <3 years at the time of diagnosis (date of surgical resection/biopsy)
  • Participant with presumed newly diagnosed tumor in the supratentorial compartment
  • Patient must have measurable disease based on RAPNO criteria
  • ≤84 days since surgery (resection or biopsy)
  • Available tumor tissue for central review
  • Parent/guardian has the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines

Exclusion Criteria: Screening Phase

  • Previous exposure to cytotoxic chemotherapy or radiotherapy

Inclusion Criteria: COHORT 1

  • Patients must be <3 years of age at the time of diagnosis (date of surgical resection/biopsy)

  • High-grade glioma (World Health Organization [WHO] grade III or IV) harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review

  • Patients must have measurable disease as defined by RAPNO criteria

  • Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation

  • ≤28 days since study screening

  • Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks

  • Neurologic deficits must have been stable for at least 7 days prior to study enrollment

  • Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)

  • Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment)

  • Absolute neutrophil count >1,000/µL

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x the upper limit of normal (ULN)

  • Bilirubin ≤ 1.5 x ULN

  • Adequate renal function as defined by the following age-based serum creatinine concentrations:

    • 0 to <1 year: 0.5 mg/dL
    • 1 to <2 years: 0.6 mg/dL
    • 2 to 3 years: 0.8 mg/dL
  • Adequate cardiac function as defined by electrocardiogram (ECG) with Fridericia's corrected QT interval (QTc) ≤ 450 msec and echocardiogram left ventricular ejection fraction (LVEF) >50%

  • Screening and enrollment consents signed

  • Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures

Inclusion Criteria: COHORT 2

  • Patients must be <3 years of age at the time of diagnosis (date of surgical resection/biopsy)

  • CNS tumor other than HGG harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review

  • Patients must have measurable disease as defined by RAPNO criteria

  • Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation

  • ≤28 days since study screening

  • Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks

  • Neurologic deficits must have been stable for at least 7 days prior to study enrollment.

  • Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)

  • Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment);

  • Absolute neutrophil count >1,000/µL.

  • ALT and ALT ≤2.5x the upper limit of normal (ULN)

  • Bilirubin ≤ 1.5 x ULN

  • Adequate renal function as defined by the following age-based serum creatinine concentrations:

    • 0 to <1 year: 0.5 mg/dL
    • 1 to <2 years: 0.6 mg/dL
    • 2 to 3 years: 0.8 mg/dL
  • Adequate cardiac function as defined by ECG with QTc ≤ 450 msec and echocardiogram LVEF >50%

  • Screening and enrollment consents signed

  • Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures

Exclusion Criteria: COHORT 1 AND 2

  • Clinically significant medical disorder that could compromise the ability to tolerate study therapy or would interfere with the study procedures or results history
  • History of recent (3 months) symptomatic congestive heart failure
  • Known active, uncontrolled infection (bacterial, fungal, or viral)
  • Receiving enzyme inducing antiepileptic drugs (EIAEDs)
  • Any prior cancer therapy including chemotherapy (excluding Bridging Chemotherapy Cycle), targeted therapy, immunotherapy, cellular therapy, or radiation
  • Receiving another investigational agent concurrently
  • Surgery within 2 weeks prior to treatment enrollment
  • Patients with known hypersensitivity to excipients of the investigational medicinal product
  • Active gastrointestinal disease or malabsorption disorder (e.g. Crohn's disease, ulcerative colitis, short-gut syndrome) that would impair drug absorption
  • Inability to take medication enterally

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Entrectinib therapy, Cohort 1 and Cohort 2

Cohort 1: Patients who are younger than 3 years of age diagnosed with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) will receive therapy as outline in Detailed Description.

Cohort 2: Patients who are younger than 3 years of age diagnosed with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG will receive therapy as outline in Detailed Description.

Given IV

Muut nimet:
  • Paraplatiini®

Given IV

Muut nimet:
  • VP-16

Given orally (PO) or enterally

Muut nimet:
  • Rozlytrek

Given intravenous (IV)

Muut nimet:
  • Cytoxan®

Given subcutaneous (SQ) or IV

Muut nimet:
  • Filgrastim

Given SQ as part of recommended Bridging Therapy instead of G-CSF.

Muut nimet:
  • Neulasta

A gross total resection or significant debulking may become possible if a response to entrectinib is seen.

Muut nimet:
  • Kirurginen resektio

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Overall response rate (ORR) (Cohort 1)
Aikaikkuna: After cycle 4 (each cycle is 28 days).

ORR is defined as the percentage of patients with either partial or complete response assessed at the protocol-defined evaluation timepoint. Overall response will be determined by the central imaging review based on the scheduled evaluations.

After cycle 4 (each cycle is 28 days).

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Progression free survival (PFS) (Cohort 1)
Aikaikkuna: At 2 and 5 years

PFS is defined as the time from initiation of protocol treatment to first event (progressive disease, death due to any cause), or date last follow-up among those who have not had an event. Described using Kaplan Meier method.

At 2 and 5 years
Overall survival (OS) (Cohort 1)
Aikaikkuna: At 2 and 5 years

OS is defined as the time from date of diagnosis to date of death due to any cause or date last follow-up. Described using Kaplan Meier method.

At 2 and 5 years
Duration of response (DOR) (Cohort 1)
Aikaikkuna: Up to 5 years

DOR is defined as time from date of first response (partial or complete) until the date of progression or last follow-up. Described as median time.

Up to 5 years
Patients who have second surgeries (Cohort 1)
Aikaikkuna: Up to 5 years

Percentage of patients who had second surgeries.

Up to 5 years
Patients who undergo gross-total resection after treatment (Cohort 1)
Aikaikkuna: Up to 5 years

Percentage of patients who underwent a gross-total resection.

Up to 5 years
ORR (Cohort 2)
Aikaikkuna: After cycle 4 (each cycle is 28 days).

ORR is defined as the percentage of patients with either partial or complete response assessed at the protocol-defined evaluation timepoint. Overall response will be determined by the central imaging review based on the scheduled evaluations.

After cycle 4 (each cycle is 28 days).
PFS (Cohort 2)
Aikaikkuna: At 2 and 5 years

PFS is defined as the time from initiation of protocol treatment to first event (progressive disease, death due to any cause), or date last follow-up among those who have not had an event. Described using Kaplan Meier method.

At 2 and 5 years
OS (Cohort 2)
Aikaikkuna: At 2 and 5 years

OS is defined as the time from date of diagnosis to date of death due to any cause or date last follow-up. Described using Kaplan Meier method.

At 2 and 5 years
DOR (Cohort 2)
Aikaikkuna: Up to 5 years

DOR is defined as time from date of first response (partial or complete) until the date of progression or last follow-up. Described as median time.

Up to 5 years
Patients who have second surgeries (Cohort 2)
Aikaikkuna: Up to 5 years

Percentage of patients who had second surgeries. [Time Frame: Up to 5 years]

Up to 5 years
Patients who undergo gross-total resection after treatment (Cohort 2)
Aikaikkuna: Up to 5 years

Percentage of patients who underwent a gross-total resection.

Up to 5 years
Incidence of adverse events (Cohort 1 and 2)
Aikaikkuna: Up to 5 years

Percentage of adverse events on therapy including Entrectinib, captured using National Cancer Institute Common Terminology Criteria for Adverse Events 5.0.

Up to 5 years
Number of patients screened versus enrolled and treated (Cohort 1 and 2)
Aikaikkuna: Up to 5 years

Number of enrolled and treated patients as a percentage of number of patients screened and eligible for study.

Up to 5 years
Time from initial diagnostic surgery to screening and enrollment (Cohort 1 and 2)
Aikaikkuna: Up to 5 years

Median time in days from initial surgery to screening and enrollment on study.

Up to 5 years

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Daniel Moreira, MD, MEd, St. Jude Children's Research Hospital

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Perjantai 1. toukokuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Maanantai 1. marraskuuta 2027

Opintojen valmistuminen (Arvioitu)

Maanantai 1. marraskuuta 2032

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 22. heinäkuuta 2024

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 25. heinäkuuta 2024

Ensimmäinen Lähetetty (Todellinen)

Tiistai 30. heinäkuuta 2024

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 3. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 2. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.

IPD-jaon aikakehys

Data will be made available at the time of article publication.

IPD-jaon käyttöoikeuskriteerit

Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA
  • ICF

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa